1 |
Wu S, Dahut WL, Gulley JL. The use of bisphosphonates in cancer patients. Acta Oncol 2007;46:581- 91
DOI
ScienceOn
|
2 |
Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104-7
DOI
ScienceOn
|
3 |
Rosenberg TJ, Ruggiero S. Osteonecrosis of the jaws associated with the use of bisphosphonates. J Oral Maxillofac Surg 2003;61:60 (letter)
DOI
ScienceOn
|
4 |
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-7
DOI
ScienceOn
|
5 |
Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. New Engl J Med 2003;21: 4253-4 (letter)
|
6 |
Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34
DOI
ScienceOn
|
7 |
Lugassy G, Shaham R, Nemets A, et al. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med 2004;117:440-1
DOI
ScienceOn
|
8 |
Bagan JV, Murillo J, Poveda R, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005;34:120-3
DOI
ScienceOn
|
9 |
Vannucchi AM, Ficarra G, Antonioli E, et al. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol 2005;128:738
DOI
ScienceOn
|
10 |
Yarom N, Yahalom Y, Shoshani, et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007;18(10):1363-70
DOI
ScienceOn
|
11 |
Lehrer S, Montazem A, Ramanathan L, Pessin- Minsley M, Pfail J, Stock RG, et al. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 106 : 389-91.
DOI
ScienceOn
|
12 |
Kos M, Kuebler JF, Luczak K, Engelke W. Bisphosphonate related osteonecrosis of the jaws: a review of 34 cases and evaluation of risk. J Craniomaxillofac Surg 2010; 38 : 255-9.
DOI
ScienceOn
|
13 |
Migliorati CA, Schubert MM, Peterson DE, et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93
DOI
ScienceOn
|
14 |
Merigo E, Manfredi M, Meleti M, et al. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four- case report. J Oral Pathol Med 2005;34:613-7
DOI
ScienceOn
|
15 |
Olson KB, Hellie CM, Pienta KJ. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. Urology 2005;66:658
|
16 |
Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single- centre experience in 303 patients. Br J Haematol 2006;134:620-3
DOI
ScienceOn
|
17 |
Sanna G, Preda L, Bruschini R, et al. Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol 2006;17:1512-6
DOI
ScienceOn
|
18 |
Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945- 52
DOI
ScienceOn
|
19 |
American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonates-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76
DOI
ScienceOn
|
20 |
Ficarra G, Beninati F. Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects. Head Neck Pathol 2007; 1 : 132-40.
DOI
ScienceOn
|
21 |
Reid IR, Bolland MJ. Is bisphosphonates-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007;41:318-20
DOI
ScienceOn
|